

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

—  
APOTEX INC.,  
Petitioner

v.

CELLGENE CORPORATION,  
Patent Owner

—  
Case IPR2023-00512  
U.S. Patent No. 8,846,628  
Issued: September 30, 2014

Title:  
ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF

**DECLARATION OF GRAHAM BUCKTON, Ph.D.**

By: \_\_\_\_\_



February 10, 2023

## **TABLE OF CONTENTS**

	<b><u>Page</u></b>
<b>I. INTRODUCTION .....</b>	<b>1</b>
<b>II. QUALIFICATIONS .....</b>	<b>2</b>
<b>III. APPLICABLE STANDARDS .....</b>	<b>5</b>
A. Person of Ordinary Skill in the Art .....	5
B. Patent Priority Date / Earliest Effective Filing Date .....	7
C. Claim Construction .....	9
D. Invalidity .....	10
1. Anticipation .....	10
2. Obviousness .....	11
<b>IV. DOCUMENTS .....</b>	<b>13</b>
<b>V. SUMMARY OF OPINIONS .....</b>	<b>17</b>
<b>VI. BACKGROUND AND STATE OF THE ART .....</b>	<b>17</b>
A. Knowledge in the Prior Art Would Have Led a POSA to the Claimed Invention .....	17
1. 5-Azacytidine Was a Long-Known Therapeutic Compound for Treating One or More Symptoms of a Disease Associated With Abnormal Cell Proliferation Such As Myelodysplastic Syndrome and Acute Myelogenous Leukemia .....	17
2. Oral Administration of 5-Azacytidine Was Known and Preferred at the Time of Invention .....	19
3. Non-enteric Coated (Non-EC) Tablets of 5-Azacytidine Were Known and Preferred .....	23
4. It Would Have Been Routine to Use Well-Known and Conventional <i>In Silico</i> Modeling to Determine the Pharmacokinetics of Oral 5-Azacytidine Dosage Forms .....	27

B.	The '628 Patent .....	30
1.	The Specification .....	30
2.	The Prosecution History .....	31
3.	The Challenged Claims.....	34
4.	Priority Date / Earliest Effective Filing Date of the Challenged Claims .....	35
C.	Claim Construction .....	37
<b>VII.</b>	<b>CLAIMS 1, 2, 6-9, 11-28, 32-36, AND 38-43 OF THE '628 PATENT ARE UNPATENTABLE.....</b>	<b>39</b>
A.	Ground 1: Claims 1, 2, 6-8, 11, 13-18, 20-23, 28, 32-35, 38, 40, 42, and 43 Are Anticipated by Ionescu .....	39
1.	Independent Claims 1 and 28: Ionescu Discloses Non-EC Tablets of 5-Azacytidine to Treat One or More Symptoms of a Disease Associated With Abnormal Cell Proliferation Such as MDS .....	39
a.	[1a] “A pharmaceutical composition for oral administration comprising” .....	40
b.	[1b] “a therapeutically effective amount of 5- azacytidine” .....	40
c.	[1c] “at least one pharmaceutically acceptable excipient” .....	41
d.	[1d] “wherein the composition is a non-enteric coated tablet” .....	41
e.	Claim 28.....	42
2.	Dependent Claims 2, 6, 7, 13-15, 32, and 34 Reciting Formulation Limitations: Ionescu Discloses a Sugar- Coated Tablet of 5-Azacytidine Comprising Mannitol, Microcrystalline Cellulose, Crospovidone, and Magnesium Stearate.....	43

a.	Dependent Claims 2 and 34 Reciting Pharmaceutically Acceptable Excipients .....	43
b.	Dependent Claims 6, 7, and 32 Reciting “Essentially Free” of Cytidine Deaminase Inhibitor, Like THU.....	44
c.	Dependent Claims 13-15 Reciting Film Coatings Like HPMC, HPC, or MC .....	45
3.	Dependent Claims 8, 16, 17, 23, 33, and 35 Reciting Dosage Limitations: Ionescu Discloses Tablets Containing “About 5 mg to 200 mg, More Usually About 100 mg” of 5-Azacytidine.....	46
a.	Dependent Claims 8, 16, 17, and 35 Reciting Various Dosage Amounts .....	47
b.	Dependent Claim 23 Reciting Dosage Amount of “120 to 480 mg” .....	47
c.	Dependent Claim 33 Reciting a “Single Unit Dosage Form” .....	49
4.	Dependent Claims 11, 18, 20-22, 38, 40, 42, and 43: Ionescu Inherently Discloses the Claimed PK Properties (AUC, C <sub>max</sub> , and T <sub>max</sub> ).....	49
B.	Ground 2: Claims 1, 2, 6-9, 11-28, 32-36, and 38-43 Would Have Been Obvious Over Ionescu in View of Atadja, Gibson, and the Knowledge of a POSA .....	52
1.	Independent Claims 1 and 28 Would Have Been Obvious .....	52
a.	A POSA Would Have Been Motivated to Pursue an Oral, Non-EC Tablet of 5-Azacytidine.....	53
i.	A POSA Would Have Been Motivated to Pursue and Select an Oral Dosage Form of 5-Azacytidine From the Dosage Forms Ionescu.....	53

ii.	A POSA Would Have Been Motivated to Pursue and Select a Non-EC Tablet of 5-Azacytidine From the Oral Dosage Forms of Ionescu .....	59
b.	A POSA Would Have Had a Reasonable Expectation of Arriving at the Claimed Compositions and Methods of Treatment .....	62
2.	Dependent Claims 2, 6, 7, 13-15, 32, and 34 Reciting Formulation Limitations Would Have Been Obvious .....	63
a.	Dependent Claims 2 and 34 Reciting Pharmaceutically Acceptable Excipients .....	63
b.	Dependent Claims 6, 7, and 32 Reciting “Essentially Free” of Cytidine Deaminase Inhibitor, Like THU .....	64
c.	Dependent Claims 13-15 Reciting Film Coatings Like HPMC, HPC, or MC .....	66
d.	A POSA Would Have Had a Reasonable Expectation of Arriving at Claims 2, 6, 7, 13-15, 32, and 34 .....	69
3.	Dependent Claims 8, 9, 16, 17, 23-27, 33, 35, and 36 Reciting Dosage Limitations Would Have Been Obvious .....	70
a.	Dependent Claims 8, 9, 16, 17, 23-27, 33, 35, and 36 Reciting Various Dosage Amounts .....	70
b.	Dependent Claim 33 Reciting a “Single Unit Dosage Form” .....	74
c.	A POSA Would Have Had a Reasonable Expectation of Arriving at Claims 8, 9, 16, 17, 23- 27, 33, 35, and 36 .....	76
4.	Dependent Claims 11, 12, 18-22, and 38-43 Reciting PK Limitations Would Have Been Obvious .....	77

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.